Test Bank For Clayton’s Basic Pharmacology for Nurses 19th Edition
c c c c c c c c c
By Michelle J. Willihnganz, Samuel L. Gurevitz, Bruce Clayton
c c c c c c c c c
Complete
c
,Chapter 01: Drug Definitions, Standards, and Information Sources
c c c c c c c
Willihnganz: Clayton’s Basic Pharmacology for Nurses, 19th Edition
c c c c c c c c
MULTIPLE cCHOICE
1. Which cname cidentifies ca cdrug clisted cbycthe cUS cFood cand
Drug cAdministration c(FDA)?
c
a. Brand
b. Nonproprietary
c. Official
d. Trademark
ANS: cC
The cofficial cname cis cthe c name cunder cwhich ca cdrug cis clisted
cby cthe cFDA. cThe cbrand cname, cor ctrademark, cis cthe cname
cgiven cto ca cdrug cby cits cmanufacturer. cThe cnonproprietary, cor
cgeneric, cname cis cprovided cby cthe cUnited cStates cAdopted
cNames cCouncil.
DIF: Cognitive cLevel: cKnowledge REF: c p. c9
OBJ: c1NAT: cNCLEX cClient cNeeds cCategory: cSafe, cEffective
cCare cEnvironment cTOP: c Nursing cProcess cStep: cAssessment CON:
cPatient cEducation
2. Which csource ccontains cinformation cspecific cto cnutritional csupplements?
a. USP cDictionary cof cUSAN c &cInternational cDrug cNames
b. Natural cMedicines cComprehensive cDatabase
c. United cStates cPharmacopoeia/National cFormulary c(USP cNF)
d. Drug cInteraction cFacts
ANS: cC
United cStates cPharmacopoeia/National cFormulary ccontains cinformation cspecific cto cnutritional
csupplements. cUSP cDictionary cof cUSAN c &cInternational cDrug cNames cis ca ccompilation cof
cdrug cnames, cpronunciation cguide, cand cpossible cfuture cFDA capproved cdrugs; cit cdoes cnot
cinclude cnutritional csupplements. cNatural cMedicines cComprehensive cDatabase ccontains
evidence-based cinformation con cherbal cmedicines cand cherbal ccombination cproducts; cit cdoes cnot
cinclude cinformation cspecific cto cnutritional csupplements. cDrug cInteraction cFacts ccontains
ccomprehensive cinformation con cdrug cinteraction cfacts; cit cdoes cnot cinclude cnutritional
csupplements.
DIF: Cognitive cLevel: cKnowledge REF: c p. c4 OBJ: c3
cNAT: c NCLEX cClient cNeeds cCategory: cPhysiological cIntegrity
TOP: c Nursing cProcess cStep: cAssessment CON: c Nutrition c|cPatient cEducation
3. Which cdrug creference ccontains cdrug cmonographs cthat cdescribe call cdrugs cin ca ctherapeutic cclass?
a. Drug cFacts cand cComparisons
, 3
b. Drug cInteraction cFacts
c. Handbook con cInjectable cDrugs
d. Martindale—The cComplete cDrug cReference
ANS: c A
Drug cFacts cand cComparisons ccontains cdrug cmonographs cthat cdescribe call cdrugs cin ca
ctherapeutic cclass. cMonographs care cformatted cas ctables cto callow ccomparison cof csimilar
cproducts, cbrand cnames, cmanufacturers, ccost cindices, cand cavailable cdosage cforms
cOnline cversion cis cavailable.
DIF: Cognitive cLevel: cKnowledge REF: c p. c4 cTable c1.2
OBJ: c c 3 NAT: c NCLEX cClient cNeeds cCategory: cPhysiological cIntegrity
TOP: c Nursing cProcess cStep: cAssessment CON: c Safety c|cPatient cEducation c|cClinical cJudgment
4. Which cdrug creference ccontains cmonographs cabout cvirtually ceverycsingle-entitycdrug cavailable
in cthe cUnited cStates cand cdescribes ctherapeutic cuses cof cdrugs, cincluding capproved cand
c
unapproved cuses?
c
a. Martindale: cThe cComplete cDrug cReference
b. AHFS cDrug cInformation
c. Drug cReference
d. Drug cFacts cand cComparisons
ANS: c B
AHFS cDrug cInformation ccontains cmonographs cabout cvirtually cevery csingle-entity cdrug
cavailable cin cthe cUnited cStates cand cdescribes ctherapeutic cuses cof cdrugs, cincluding capproved cand
cunapproved cuses.
DIF: Cognitive cLevel: cKnowledge REF: c p. c4 cTable c1.2
OBJ: c c 3 NAT: c NCLEX cClient cNeeds cCategory: cPhysiological cIntegrity
TOP: c Nursing cProcess cStep: cPlanning CON: c Safety c|cPatient cEducation c|cClinical cJudgment
5. Which conline cdrug creference cmakes cavailable cto chealthcare cproviders cand cthe cpublic ca
standard, ccomprehensive, cup-to-date clook cup cand cdownloadable cresource cabout cmedicines?
c
a. American cDrug cIndex
b. American cHospital cFormulary
c. DailyMed
d. Drug cReference
ANS: cC
DailyMed cmakes cavailable cto chealthcare cproviders cand cthe cpublic ca cstandard, ccomprehensive,
cup-to-date clook cup cand cdownloadable cresource cabout cmedicines. cThe cAmerican cDrug cIndex
cis cnot cappropriate cfor cpatient cuse. cThe cAmerican cHospital cFormulary cis cnot cappropriate cfor
cpatient cuse. cThe cdrug creference cis cnot cappropriate cfor cpatient cuse.
DIF: Cognitive cLevel: cKnowledge REF: c p. c3 c| cp. c4 OBJ: c3
cNAT: c NCLEX cClient cNeeds cCategory: cPhysiological cIntegrity
TOP: cNursing cProcess cStep: cImplementation
CON: c Safety c| cPatient cEducation c| cClinical cJudgment
6. Which clegislation cauthorizes cthe cFDA cto cdetermine cthe csafetycof ca cdrug cbefore cits cmarketing?
a. Federal cFood, cDrug, cand cCosmetic cAct c(1938)
b. Durham cHumphreycAmendment c(1952)
, 4
c. Controlled cSubstances cAct c(1970)
d. Kefauver cHarris cDrug cAmendment c(1962)
ANS: c A
The cFederal cFood, cDrug, cand cCosmetic cAct cof c1938 cauthorized cthe cFDA cto cdetermine cthe
csafety cof call cdrugs cbefore cmarketing. cLater camendments cand cacts chelped ctighten cFDA
ccontrol cand censure cdrug csafety. cThe cDurham cHumphrey cAmendment cdefines cthe ckinds cof
cdrugs cthat ccannot cbe cused csafely cwithout cmedical csupervision cand crestricts ctheir csale cto
cprescription cby ca clicensed cpractitioner. cThe cControlled cSubstances cAct caddresses conly
ccontrolled csubstances cand ctheir ccategorization. cThe cKefauver cHarris cDrug cAmendment
censures cdrug cefficacy cand cgreater cdrug csafety. cDrug cmanufacturers care crequired cto cprove cto
cthe cFDA cthe ceffectiveness cof ctheir cproducts cbefore cmarketing cthem.
DIF: Cognitive cLevel: cKnowledge REF: c p. c5 cTable cl.3
OBJ: c 5 NAT: cNCLEX cClient cNeeds cCategory: cPhysiological cIntegrity
cTOP: c Nursing cProcess cStep: cAssessment
CON: c Safety c|cPatient cEducation c| cEvidence c| cHealth cCare cLaw
7. Which cclassification cdoes cmeperidine c(Demerol) cfall cunder?
a. I
b. II
c. III
d. IV
ANS: c B
Meperidine c(Demerol) cis ca cSchedule cII cdrug; cit chas ca chigh cpotential cfor cabuse cand cmay clead
cto csevere cpsychological cand cphysical cdependence. cSchedule cI cdrugs chave chigh cpotential cfor
cabuse cand cno crecognized cmedical cuse. cSchedule cIII cdrugs chave csome cpotential cfor cabuse.
cUse cmay clead cto clow cto cmoderate cphysical cdependence cor chigh cpsychological cdependence.
cSchedule cIV cdrugs chave clow cpotential cfor cabuse. cUse cmay clead cto climited cphysical cor
cpsychological cdependence.
DIF: Cognitive cLevel: cKnowledge REF: c p. c10 OBJ: c2
cNAT: c NCLEX cClient cNeeds cCategory: cSafe, cEffective cCare
cEnvironment
TOP: c Nursing cProcess cStep: cAssessment CON: c Patient cEducation c|cAddiction c|cPain
8. Which caction cwould cthe cFDA ctake cto cexpedite cdrug cdevelopment cand capproval cfor can coutbreak
of csmallpox?
c
a. List csmallpox cas ca chealth corphan cdisease.
b. Omit cthe cpreclinical cresearch cphase.
c. Extend cthe cclinical cresearch cphase.
d. Fast ctrack cthe cinvestigational cdrug.
ANS: cD
Once cthe cInvestigational cNew cDrug cApplication chas cbeen capproved, cthe cdrug ccan creceive
chighest cpriority cwithin cthe cagency, cwhich cis ccalled cfast ctracking. cA csmallpox coutbreak
cwould cbecome ca cpriority cconcern cin cthe cworld. cOrphan cdiseases care cnot cresearched cin ca
cpriority cmanner. cPreclinical cresearch cis cnot comitted. cExtending cany cphase cof cthe cresearch
cwould cmean ca clonger ctime cto cdevelop ca cvaccine. cThe cFDA cmust censure cthat call cphases cof cthe
cpreclinical cand cclinical cresearch cphase chave cbeen ccompleted cin ca csafe cmanner.
DIF: Cognitive cLevel: cKnowledge REF: c c p. c7 OBJ: c 5
c c c c c c c c c
By Michelle J. Willihnganz, Samuel L. Gurevitz, Bruce Clayton
c c c c c c c c c
Complete
c
,Chapter 01: Drug Definitions, Standards, and Information Sources
c c c c c c c
Willihnganz: Clayton’s Basic Pharmacology for Nurses, 19th Edition
c c c c c c c c
MULTIPLE cCHOICE
1. Which cname cidentifies ca cdrug clisted cbycthe cUS cFood cand
Drug cAdministration c(FDA)?
c
a. Brand
b. Nonproprietary
c. Official
d. Trademark
ANS: cC
The cofficial cname cis cthe c name cunder cwhich ca cdrug cis clisted
cby cthe cFDA. cThe cbrand cname, cor ctrademark, cis cthe cname
cgiven cto ca cdrug cby cits cmanufacturer. cThe cnonproprietary, cor
cgeneric, cname cis cprovided cby cthe cUnited cStates cAdopted
cNames cCouncil.
DIF: Cognitive cLevel: cKnowledge REF: c p. c9
OBJ: c1NAT: cNCLEX cClient cNeeds cCategory: cSafe, cEffective
cCare cEnvironment cTOP: c Nursing cProcess cStep: cAssessment CON:
cPatient cEducation
2. Which csource ccontains cinformation cspecific cto cnutritional csupplements?
a. USP cDictionary cof cUSAN c &cInternational cDrug cNames
b. Natural cMedicines cComprehensive cDatabase
c. United cStates cPharmacopoeia/National cFormulary c(USP cNF)
d. Drug cInteraction cFacts
ANS: cC
United cStates cPharmacopoeia/National cFormulary ccontains cinformation cspecific cto cnutritional
csupplements. cUSP cDictionary cof cUSAN c &cInternational cDrug cNames cis ca ccompilation cof
cdrug cnames, cpronunciation cguide, cand cpossible cfuture cFDA capproved cdrugs; cit cdoes cnot
cinclude cnutritional csupplements. cNatural cMedicines cComprehensive cDatabase ccontains
evidence-based cinformation con cherbal cmedicines cand cherbal ccombination cproducts; cit cdoes cnot
cinclude cinformation cspecific cto cnutritional csupplements. cDrug cInteraction cFacts ccontains
ccomprehensive cinformation con cdrug cinteraction cfacts; cit cdoes cnot cinclude cnutritional
csupplements.
DIF: Cognitive cLevel: cKnowledge REF: c p. c4 OBJ: c3
cNAT: c NCLEX cClient cNeeds cCategory: cPhysiological cIntegrity
TOP: c Nursing cProcess cStep: cAssessment CON: c Nutrition c|cPatient cEducation
3. Which cdrug creference ccontains cdrug cmonographs cthat cdescribe call cdrugs cin ca ctherapeutic cclass?
a. Drug cFacts cand cComparisons
, 3
b. Drug cInteraction cFacts
c. Handbook con cInjectable cDrugs
d. Martindale—The cComplete cDrug cReference
ANS: c A
Drug cFacts cand cComparisons ccontains cdrug cmonographs cthat cdescribe call cdrugs cin ca
ctherapeutic cclass. cMonographs care cformatted cas ctables cto callow ccomparison cof csimilar
cproducts, cbrand cnames, cmanufacturers, ccost cindices, cand cavailable cdosage cforms
cOnline cversion cis cavailable.
DIF: Cognitive cLevel: cKnowledge REF: c p. c4 cTable c1.2
OBJ: c c 3 NAT: c NCLEX cClient cNeeds cCategory: cPhysiological cIntegrity
TOP: c Nursing cProcess cStep: cAssessment CON: c Safety c|cPatient cEducation c|cClinical cJudgment
4. Which cdrug creference ccontains cmonographs cabout cvirtually ceverycsingle-entitycdrug cavailable
in cthe cUnited cStates cand cdescribes ctherapeutic cuses cof cdrugs, cincluding capproved cand
c
unapproved cuses?
c
a. Martindale: cThe cComplete cDrug cReference
b. AHFS cDrug cInformation
c. Drug cReference
d. Drug cFacts cand cComparisons
ANS: c B
AHFS cDrug cInformation ccontains cmonographs cabout cvirtually cevery csingle-entity cdrug
cavailable cin cthe cUnited cStates cand cdescribes ctherapeutic cuses cof cdrugs, cincluding capproved cand
cunapproved cuses.
DIF: Cognitive cLevel: cKnowledge REF: c p. c4 cTable c1.2
OBJ: c c 3 NAT: c NCLEX cClient cNeeds cCategory: cPhysiological cIntegrity
TOP: c Nursing cProcess cStep: cPlanning CON: c Safety c|cPatient cEducation c|cClinical cJudgment
5. Which conline cdrug creference cmakes cavailable cto chealthcare cproviders cand cthe cpublic ca
standard, ccomprehensive, cup-to-date clook cup cand cdownloadable cresource cabout cmedicines?
c
a. American cDrug cIndex
b. American cHospital cFormulary
c. DailyMed
d. Drug cReference
ANS: cC
DailyMed cmakes cavailable cto chealthcare cproviders cand cthe cpublic ca cstandard, ccomprehensive,
cup-to-date clook cup cand cdownloadable cresource cabout cmedicines. cThe cAmerican cDrug cIndex
cis cnot cappropriate cfor cpatient cuse. cThe cAmerican cHospital cFormulary cis cnot cappropriate cfor
cpatient cuse. cThe cdrug creference cis cnot cappropriate cfor cpatient cuse.
DIF: Cognitive cLevel: cKnowledge REF: c p. c3 c| cp. c4 OBJ: c3
cNAT: c NCLEX cClient cNeeds cCategory: cPhysiological cIntegrity
TOP: cNursing cProcess cStep: cImplementation
CON: c Safety c| cPatient cEducation c| cClinical cJudgment
6. Which clegislation cauthorizes cthe cFDA cto cdetermine cthe csafetycof ca cdrug cbefore cits cmarketing?
a. Federal cFood, cDrug, cand cCosmetic cAct c(1938)
b. Durham cHumphreycAmendment c(1952)
, 4
c. Controlled cSubstances cAct c(1970)
d. Kefauver cHarris cDrug cAmendment c(1962)
ANS: c A
The cFederal cFood, cDrug, cand cCosmetic cAct cof c1938 cauthorized cthe cFDA cto cdetermine cthe
csafety cof call cdrugs cbefore cmarketing. cLater camendments cand cacts chelped ctighten cFDA
ccontrol cand censure cdrug csafety. cThe cDurham cHumphrey cAmendment cdefines cthe ckinds cof
cdrugs cthat ccannot cbe cused csafely cwithout cmedical csupervision cand crestricts ctheir csale cto
cprescription cby ca clicensed cpractitioner. cThe cControlled cSubstances cAct caddresses conly
ccontrolled csubstances cand ctheir ccategorization. cThe cKefauver cHarris cDrug cAmendment
censures cdrug cefficacy cand cgreater cdrug csafety. cDrug cmanufacturers care crequired cto cprove cto
cthe cFDA cthe ceffectiveness cof ctheir cproducts cbefore cmarketing cthem.
DIF: Cognitive cLevel: cKnowledge REF: c p. c5 cTable cl.3
OBJ: c 5 NAT: cNCLEX cClient cNeeds cCategory: cPhysiological cIntegrity
cTOP: c Nursing cProcess cStep: cAssessment
CON: c Safety c|cPatient cEducation c| cEvidence c| cHealth cCare cLaw
7. Which cclassification cdoes cmeperidine c(Demerol) cfall cunder?
a. I
b. II
c. III
d. IV
ANS: c B
Meperidine c(Demerol) cis ca cSchedule cII cdrug; cit chas ca chigh cpotential cfor cabuse cand cmay clead
cto csevere cpsychological cand cphysical cdependence. cSchedule cI cdrugs chave chigh cpotential cfor
cabuse cand cno crecognized cmedical cuse. cSchedule cIII cdrugs chave csome cpotential cfor cabuse.
cUse cmay clead cto clow cto cmoderate cphysical cdependence cor chigh cpsychological cdependence.
cSchedule cIV cdrugs chave clow cpotential cfor cabuse. cUse cmay clead cto climited cphysical cor
cpsychological cdependence.
DIF: Cognitive cLevel: cKnowledge REF: c p. c10 OBJ: c2
cNAT: c NCLEX cClient cNeeds cCategory: cSafe, cEffective cCare
cEnvironment
TOP: c Nursing cProcess cStep: cAssessment CON: c Patient cEducation c|cAddiction c|cPain
8. Which caction cwould cthe cFDA ctake cto cexpedite cdrug cdevelopment cand capproval cfor can coutbreak
of csmallpox?
c
a. List csmallpox cas ca chealth corphan cdisease.
b. Omit cthe cpreclinical cresearch cphase.
c. Extend cthe cclinical cresearch cphase.
d. Fast ctrack cthe cinvestigational cdrug.
ANS: cD
Once cthe cInvestigational cNew cDrug cApplication chas cbeen capproved, cthe cdrug ccan creceive
chighest cpriority cwithin cthe cagency, cwhich cis ccalled cfast ctracking. cA csmallpox coutbreak
cwould cbecome ca cpriority cconcern cin cthe cworld. cOrphan cdiseases care cnot cresearched cin ca
cpriority cmanner. cPreclinical cresearch cis cnot comitted. cExtending cany cphase cof cthe cresearch
cwould cmean ca clonger ctime cto cdevelop ca cvaccine. cThe cFDA cmust censure cthat call cphases cof cthe
cpreclinical cand cclinical cresearch cphase chave cbeen ccompleted cin ca csafe cmanner.
DIF: Cognitive cLevel: cKnowledge REF: c c p. c7 OBJ: c 5
